Gallbladder Cancer
120
13
18
61
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
17 trials with published results (14%)
Research Maturity
61 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.8%
13 terminated out of 120 trials
82.4%
-4.2% vs benchmark
7%
8 trials in Phase 3/4
28%
17 of 61 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 61 completed trials
Clinical Trials (120)
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Predicting Incidental Gallbladder Cancer
AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer
Integrated Cancer Repository for Cancer Research
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
EULAT Eradicate GBC
The PLATON Network
STALL vs Sole Local Wound Infiltration in Laparoscopic Cholecystectomy
Biomarker Discovery in Patients With Advanced Biliary Tract Cancer
Artificial Intelligence-based Tumor Microenvironment Analysis for Prognosis Prediction in Gallbladder Cancer
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
Global Evaluation of Cholecystectomy Knowledge and Outcomes
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer